PSMA-PET引导高风险复发前列腺癌大剂量放疗的中期结局
该回顾性研究纳入2013至2015年间接受挽救性放疗的高危或极高危前列腺癌患者22例,放疗前均行PSMA-PET检查并据此规划靶区。PSMA-PET使77%患者的治疗决策发生改变,治疗相关毒性低,中位随访29个月时多数患者出现持久PSA反应。
要点
- PSMA-PET使77%挽救性放疗患者的治疗决策发生改变。
- 仅2例患者出现>1级毒性,治疗耐受性良好。
- 可随访患者中14/20例出现持久PSA反应低于基线。
核心结论
- PSMA-PET引导放疗规划使多数高危复发前列腺癌患者的治疗发生改变。
- 治疗相关毒性耐受良好,中期PSA下降结果令人鼓舞。
研究设计与样本
- 回顾性研究,纳入2013至2015年间转诊行挽救性放疗的高危或极高危前列腺癌患者22例。
- 所有患者治疗前接受PSMA-PET,并基于PET数据规划放疗,对宏观肿瘤/转移灶加量。
- 毒性采用CTCAE v4.0评估,因回顾性评价未进行试验注册。
主要发现
- PSMA-PET所见使77%的挽救性放疗患者治疗较可用CT信息发生改变。
- 1例患者因播散性疾病未接受照射,其余患者接受对宏观病灶的加量照射和/或增加靶区。
- 仅2例患者报告>1级毒性。
- 中位随访29个月(未失访患者)时,多数患者(14/20)出现持久PSA反应低于基线。
- 激素初治挽救性放疗患者(n=11)中8/11例出现持久PSA下降,其中3例在随访期间因新病灶接受重复PSMA引导照射。
临床怎么用
- 对高危或极高危复发前列腺癌患者,可考虑以PSMA-PET引导挽救性放疗规划。
- 基于PSMA-PET对宏观病灶加量或增加靶区可使多数患者治疗决策改变。
局限性
- 回顾性研究,未进行试验注册。
- 样本量小(挽救性放疗n=22),中位随访29个月。
- 原文未报告对照设计、P值或置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: By the use of PSMA positron emission tomography (PET) detection of prostate cancer lesions with a high sensitivity and specificity combined with a favorable lesion to background contrast is feasible. Therefore, PSMA-PET is increasingly used for planning of radiotherapy treatment; however, any data on intermediate-term outcome is missing so far. METHODS: Patients with high-risk or very high risk prostate cancer, referred for salvage radiotherapy (SRT, n = 22) between 2013 and 2015, underwent PSMA-PET prior to therapy. Irradiation was planned on PET data with boost to macroscopic tumors/metastases. Treatment related toxicity was measured using Common Terminology Criteria for Adverse Events (CTCAE, v4.0). RESULT: Findings in PSMA-PET led to treatment modifications in 77% of SRT patients compared to available CT information. One patient did not receive irradiation due to disseminated disease, the other patients received increased boost doses to macroscopic disease and/or inclusion of additional target volumes. Toxicity was low as only 2 patients reported toxicities > grade 1. With a Median follow-up time of 29 in patients that were not lost to follow-up, prolonged PSA responses below baseline were observed in the majority of patients (14 of 20). In hormone-naïve SRT patients (n = 11), radiotherapy led to prolonged PSA decrease in 8/11 patients, however with 3 of these 8 patients receiving repeated PSMA based irradiation of novel lesions during follow-up. CONCLUSION: PSMA-PET guided planning of radiotherapy led to change of treatment in the majority of patients. Treatment related toxicity was well tolerated and promising results regarding intermediate-term PSA decrease were observed. TRIAL REGISTRATION: No trial registration was performed due to retrospective evaluation.
引用
- Zschaeck S, Wust P, Beck M, et al. Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiat Oncol. 2017. PMID: 28830532. doi:10.1186/s13014-017-0877-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。